Press Release

Amyotrophic Lateral Sclerosis Treatment Market Size to Witness CAGR of 6.9% from 2019-2025
October 2020

Amyotrophic Lateral Sclerosis Treatment Market Size to Witness CAGR of 6.9% from 2019-2025

According to iCognition Insights, the global amyotrophic lateral sclerosis (ALS) treatment market size is estimated to be USD 625.0 million in 2019. Increasing geriatric population globally, rising awareness of ALS, and growing incidence of ALS are some of the key factors boosting growth of the global market. However, high cost related with ALS treatment is expected to hinder the market growth during the forecast period.

Based on treatment, the amyotrophic lateral sclerosis treatment market is segmented into stem cell therapies, medications, and others. In 2019, the medications segment was the highest revenue-grossing segment. Based on distribution channel, the ALS treatment market is categorized into hospitals, retail pharmacies, and others.

In 2019, North America was the highest revenue-generating region in the global market and is expected to maintain its dominance during the forecast period. This is attributed to the well-developed healthcare expenditure, favourable reimbursement policies, growing healthcare expenditure, and increasing demand for advanced therapies.

Some of the key players in the amyotrophic lateral sclerosis treatment market are Otsuka Pharmaceutical Co., Ltd. (Japan); Biogen Inc. (U.S.); BrainStorm Therapeutics (U.S.); Mitsubishi Tanabe Pharma Corporation (Japan); AB Science (France); Corestem (South Korea); Biohaven Pharmaceutical (U.S.); F.Hoffmann-La Roche AG (Switzerland); Ionis Pharmaceuticals, Inc. (U.S.); and Sun Pharmaceutical (India).

Amyotrophic Lateral Sclerosis Treatment Market: Key Datapoints-

  • Increasing geriatric population globally, rising awareness of ALS, and growing incidence of ALS are the key factors boosting growth of the global market
  • The stem cell therapies treatment segment is expected to grow at a fastest CAGR during the forecast period. This is attributed to the rising demand for advanced treatment alternatives and new approaches for the management of ALS
  • The Hospitals distribution channel segment was the highest revenue-generating segment in 2019 and is estimated to hold its dominant position during the forecast period
  • Asia Pacific is projected to show the fastest CAGR over the forecast period owing to the rising prevalence of ALS, increasing R&D investment, developing healthcare infrastructure, and unmet medical needs in this region
  • Leading companies in the ALS treatment market adopt different strategies such as geographical expansion in developing markets, new product development, and strategic alliances to achieve a competitive edge

Amyotrophic Lateral Sclerosis Treatment Market Scope-

Amyotrophic Lateral Sclerosis (ALS) Treatment Market, By Technology (Revenue, 2017-2025, USD Million)

  • Medication
  • Stem Cell Therapy
  • Others

Amyotrophic Lateral Sclerosis (ALS) Treatment Market, By Distribution Channel (Revenue, 2017-2025, USD Million)

  • Hospitals
  • Retail Pharmacies
  • Others

Amyotrophic Lateral Sclerosis (ALS) Treatment Market, By Region (Revenue, 2017-2025, USD Million)

  • North America
    • US
    • Canada
  • Europe
    • Germany
    • France
    • UK
    • Spain
    • Italy
    • Russia
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of APAC
  • Latin America
    • Brazil
    • Mexico
    • Argentina
    • Rest of LATAM
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • Rest of MEA

Request a free sample copy or view report summary:

Amyotrophic Lateral Sclerosis Treatment Market